Optimized nonviral LNP system for hFVIII, P-FVIII-101, normalizes clotting efficacy in models of hemophilia A
May 22, 2024
Researchers from Poseida Therapeutics Inc. presented preclinical data for P-FVIII-101, a novel nonviral gene therapy being developed for the treatment of hemophilia A.
